Patricia Carr, Senior Vice President and Chief Accounting Officer at Jazz Pharmaceuticals (NASDAQ:JAZZ), recently sold 53 ordinary shares of the company, according to a filing with the Securities and Exchange Commission. The shares were sold at a price of $122.49 each, totaling approximately $6,491. The transaction occurs as Jazz demonstrates robust financial health with impressive gross profit margins of 92.6% and strong liquidity metrics, according to InvestingPro data. Following this transaction, Carr holds 6,596 shares in the company. The shares sold were part of an acquisition under a Section 423 Employee Stock Purchase Plan on November 29, 2024. InvestingPro analysis indicates Jazz Pharmaceuticals is currently trading below its Fair Value, with 8 additional exclusive insights available to subscribers. Access the comprehensive Pro Research Report for deep-dive analysis of JAZZ and 1,400+ other top stocks.
In other recent news, Jazz Pharmaceuticals has made a series of significant financial moves and received positive analyst ratings. The company expanded its revolving credit facility from $500 million to $885 million and extended its maturity date, providing it with added financial flexibility. Jefferies, Baird, and TD Cowen have all issued positive ratings for the company, with Jefferies and Baird raising their price targets based on projected revenue growth and the successful performance of key medications like Xywav.
Meanwhile, the FDA's recent accelerated approval of zanidatamab, a therapy for previously treated, unresectable or metastatic HER2+ biliary tract cancer, has been a significant milestone for Jazz Pharmaceuticals. This approval, alongside the anticipation of phase 3 topline Progression-Free Survival results for zanidatamab in 2025, indicates potential growth areas for the company.
On the other hand, Piper Sandler slightly decreased its price target for Jazz Pharmaceuticals, despite maintaining an Overweight rating. This adjustment occurred amid a significant drop in the company's share value, which fell approximately 30% since the acquisition of GW Pharmaceuticals (OTC:GWPRF).
These recent developments underscore Jazz Pharmaceuticals' strategic initiatives and potential growth areas, providing investors with a clear picture of the company's current standing and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.